Evidence map›Paper›PMID 40439429›Full record

ArticlemSphere2025

Application of a high-resolution melt assay for monitoring SARS-CoV-2 variants in Burkina Faso and Kenya.

Caitlin Greenland-Bews, Sonal Shah, Morine Achieng, Emilie S Badoum, Yaya Bah, Hellen C Barsosio, Helena Brazal-Monzó, Jennifer Canizales, Anna Drabko, Alice J Fraser and 27 more

Abstract read
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Caitlin Greenland-BewsThe Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.ORCID 0000-0003-3374-1385
Sonal ShahDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Morine AchiengCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kisumu County, Kenya.
Emilie S BadoumGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Yaya BahMedical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, Gambia.
Hellen C BarsosioThe Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Helena Brazal-MonzóDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Jennifer CanizalesNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Anna DrabkoQuantitative Engineering Design (QED), Sheridan, Wyoming, USA.
Alice J FraserThe Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Luke HannanDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Sheikh JarjuMedical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, Gambia.
Jean-Moise KaboréGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Mariama A KujabiMedical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, Gambia.
Cristina LeggioUK-Public Health Rapid Support Team (UK-PHRST), UK Health Security Agency (UKHSA), London, United Kingdom.
Maia LesoskyNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Jarra MannehMedical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, Gambia.
Tegwen MarlaisDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Julian MatthewmanFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Issa NebiéGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Eric OnyangoCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kisumu County, Kenya.
Alphonse OuedraogoGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Kephas OtienoThe Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Samuel S SermeGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Sodiomon SirimaGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Ben SoulamaGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Brian TangaraThe Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Alfred TionoGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
William WuQuantitative Engineering Design (QED), Sheridan, Wyoming, USA.
Emily R AdamsDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Abdul Karim SesayMedical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, Gambia.
Chris DrakeleyDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Feiko O Ter KuileCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kisumu County, Kenya.
Issiaka SoulamaGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.ORCID 0000-0002-0993-0525
Simon KariukiThe Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
David J AllenDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0002-1194-0415
Thomas EdwardsThe Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.ORCID 0000-0003-4058-4461

Funding

Bill and Melinda Gates Foundation INV-017985,INV-019400Gates Foundation INV-017985Gates Foundation INV-019400National Environment Research Council NE/V010441/1National Institute for Health Research Health Protection Research Unit NIHR200907UKPHRST RST6_00_03 EPIDZK3828U.S Food and Drug Administration Medical Countermeasures Initiative Contract 75F40120C00085
6 · The paper itself

Abstract

The rapid emergence and global dissemination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlighted a need for robust, adaptable surveillance systems. However, financial and infrastructure requirements for whole-genome sequencing mean most surveillance data have come from higher-resource geographies, despite unprecedented investment in sequencing in low- and middle-income countries (LMICs). Consequently, the molecular epidemiology of SARS-CoV-2 in some LMICs is limited, and there is a need for more cost-accessible technologies to help close data gaps for surveillance of SARS-CoV-2 variants. To address this, we have developed two high-resolution melt (HRM) curve assays that target variant-defining mutations in the SARS-CoV-2 genome, which give unique signature profiles that define different SARS-CoV-2 variants of concern (VOCs). Extracted RNA from SARS-CoV-2-positive samples collected from 205 participants (112 in Burkina Faso, 93 in Kenya) enrolled in the MALCOV study (Malaria as a Risk Factor for COVID-19) between February 2021 and February 2022 were analyzed using our optimized HRM assays. With next-generation sequencing on Oxford Nanopore MinION as a reference, two HRM assays, HRM-VOC-1 and HRM-VOC-2, demonstrated sensitivity/specificity of 100%/99.29% and 92.86%/99.39%, respectively, for detecting Alpha, 90.08%/100% and 92.31%/100% for Delta, and 93.75%/100% and 100%/99.38% for Omicron BA.1. The assays described here provide a lower-cost approach to conducting molecular epidemiology, capable of high-throughput testing. We successfully scaled up the HRM-VOC-2 assay to screen a total of 506 samples from which we were able to show the replacement of Alpha with the introduction of Delta and the replacement of Delta by the Omicron variant in this community in Kisumu, Kenya.IMPORTANCEThe rapid evolution of the severe acute respiratory syndrome coronavirus 2 variants of concern (VOCs) demonstrated the need for accessible surveillance tools so all communities can conduct viral surveillance. Sequencing, the gold standard, is still a largely inaccessible methodology in low-resource settings. Here, we present a quick, low-cost tool to screen for the common VOCs, designed to support surveillance efforts in low-resource settings. This tool was used to screen samples from Burkina Faso and Western Kenya throughout the pandemic. We show through comparison to sequencing that our assay can generate highly similar data on the different variants circulating in a population, therefore showing the effectiveness of our tool. While not a replacement for sequencing, we present a method of screening and prioritizing samples for further investigation and reduce overburdening sequencing capacity. Our findings provide insight into one potential tool that could be further applied to pathogen screening in the absence of robust sequencing infrastructure.

Indexed as

COVID-19SARS-CoV-2Burkina FasoFemaleGenome, ViralHumansKenyaMaleMutationRNA, ViralRNA, ViralAfricaBurkina FasoCOVID-19diagnosticsHRMKenyaSARS-CoV-2surveillancevariants of concern

Identifiers

PMID40439429
PMCPMC12188703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.